OBJECTIVE: Divalproex has been found efficacious in treating adolescents with and at high risk for bipolar disorder (BD), but little is known about the effects of mood stabilizers on the brain itself. We sought to examine the effects of divalproex on the structure, chemistry, and function of specific brain regions in children at high-risk for BD. METHODS: A total of 24 children with mood dysregulation but not full BD, all offspring of a parent with BD, were treated with divalproex monotherapy for 12 weeks. A subset of 11 subjects and 6 healthy controls were scanned with magnetic resonance imaging (MRI, magnetic resonance spectroscopy [MRS], and functional MRI [fMRI]) at baseline and after 12 weeks. RESULTS: There were no significant changes in amygdalar or cortical volume found over 12 weeks. Furthermore, no changes in neurometabolite ratios were found. However, we found the degree of decrease in prefrontal brain activation to correlate with degree of decrease in depressive symptom severity. CONCLUSIONS: Bipolar offspring at high risk for BD did not show gross morphometric, neurometabolite, or functional changes after 12 weeks of treatment with divalproex. Potential reasons include small sample size, short exposure to medications, or lack of significant neurobiological impact of divalproex in this particular population.
OBJECTIVE:Divalproex has been found efficacious in treating adolescents with and at high risk for bipolar disorder (BD), but little is known about the effects of mood stabilizers on the brain itself. We sought to examine the effects of divalproex on the structure, chemistry, and function of specific brain regions in children at high-risk for BD. METHODS: A total of 24 children with mood dysregulation but not full BD, all offspring of a parent with BD, were treated with divalproex monotherapy for 12 weeks. A subset of 11 subjects and 6 healthy controls were scanned with magnetic resonance imaging (MRI, magnetic resonance spectroscopy [MRS], and functional MRI [fMRI]) at baseline and after 12 weeks. RESULTS: There were no significant changes in amygdalar or cortical volume found over 12 weeks. Furthermore, no changes in neurometabolite ratios were found. However, we found the degree of decrease in prefrontal brain activation to correlate with degree of decrease in depressive symptom severity. CONCLUSIONS: Bipolar offspring at high risk for BD did not show gross morphometric, neurometabolite, or functional changes after 12 weeks of treatment with divalproex. Potential reasons include small sample size, short exposure to medications, or lack of significant neurobiological impact of divalproex in this particular population.
Authors: Cecile D Ladouceur; Jorge R C Almeida; Boris Birmaher; David A Axelson; Sharon Nau; Catherine Kalas; Kelly Monk; David J Kupfer; Mary L Phillips Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-05 Impact factor: 8.829
Authors: Melissa P DelBello; Kim M Cecil; Caleb M Adler; John P Daniels; Stephen M Strakowski Journal: Neuropsychopharmacology Date: 2006-06 Impact factor: 7.853
Authors: Kim A Gallelli; Christopher M Wagner; Asya Karchemskiy; Meghan Howe; Daniel Spielman; Allan Reiss; Kiki D Chang Journal: Bipolar Disord Date: 2005-12 Impact factor: 6.744
Authors: Manpreet K Singh; Melissa P Delbello; Caleb M Adler; Kevin E Stanford; Stephen M Strakowski Journal: J Am Acad Child Adolesc Psychiatry Date: 2008-05 Impact factor: 8.829
Authors: Nick C Patel; Melissa P DelBello; Kim M Cecil; Kevin E Stanford; Caleb M Adler; Stephen M Strakowski Journal: J Child Adolesc Psychopharmacol Date: 2008-04 Impact factor: 2.576
Authors: Robert L Findling; Thomas W Frazier; Eric A Youngstrom; Nora K McNamara; Robert J Stansbrey; Barbara L Gracious; Michael D Reed; Christine A Demeter; Joseph R Calabrese Journal: J Clin Psychiatry Date: 2007-05 Impact factor: 4.384
Authors: Manpreet K Singh; Booil Jo; Nancy E Adleman; Meghan Howe; Layla Bararpour; Ryan G Kelley; Daniel Spielman; Kiki D Chang Journal: Psychiatry Res Date: 2013-09-09 Impact factor: 3.222
Authors: Mani N Pavuluri; Alessandra M Passarotti; Jacklynn M Fitzgerald; Ezra Wegbreit; John A Sweeney Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Michele A Bertocci; Genna Bebko; Amanda Dwojak; Satish Iyengar; Cecile D Ladouceur; Jay C Fournier; Amelia Versace; Susan B Perlman; Jorge R C Almeida; Michael J Travis; Mary Kay Gill; Lisa Bonar; Claudiu Schirda; Vaibhav A Diwadkar; Jeffrey L Sunshine; Scott K Holland; Robert A Kowatch; Boris Birmaher; David Axelson; Sarah M Horwitz; Thomas Frazier; L Eugene Arnold; Mary A Fristad; Eric A Youngstrom; Robert L Findling; Mary L Phillips Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-05
Authors: D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw Journal: AJNR Am J Neuroradiol Date: 2014-02-20 Impact factor: 3.825
Authors: Amy S Garrett; David J Miklowitz; Meghan E Howe; Manpreet K Singh; Tenah K Acquaye; Christopher G Hawkey; Gary H Glover; Allan L Reiss; Kiki D Chang Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2014-10-02 Impact factor: 5.067
Authors: Douglas G Kondo; Tracy L Hellem; Young-Hoon Sung; Namkug Kim; Eun-Kee Jeong; Kristen K Delmastro; Xianfeng Shi; Perry F Renshaw Journal: Depress Res Treat Date: 2010-10-04